VIA Pharmaceuticals, Inc.
750 Battery Street
Suite 330
San Francisco,
CA 94111
United States - Map
Phone: 415-283-2200
Fax: 415-283-2201
Web Site: http://www.viapharmaceuticals.com
| VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the research and development of compounds for the treatment cardiovascular and metabolic diseases. The company is building a pipeline of small-molecule drugs that target inflammation in the blood vessel wall, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. Its principal product, VIA-2291, is in Phase II clinical trials in patients with acute coronary syndrome and patients with stenosis of the carotid artery. The company has agreements with Hoffmann-LaRoche Inc. and Hoffmann-LaRoche Ltd. to develop and commercialize two sets of compounds for the treatment of cardiovascular and metabolic disease. VIA Pharmaceuticals was founded in 2004 and is headquartered in San Francisco, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Lawrence K. Cohen Ph.D., 55
Chief Exec. Officer, Pres |
$
385.00K | N/A | Mr. James G. Stewart , 55
Chief Financial Officer, Principal Accounting Officer, Sr. VP and Sec. |
$
325.00K | N/A | Dr. Rebecca A. Taub M.D., 57
Sr. VP of R&D |
$
289.00K | N/A | Dr. Brendan P. Rae PhD, JD,
Sr. VP of Licensing and Bus. Devel. |
N/A
| N/A | Dr. Thomas Quertermous MD, FACC,
Chief Scientific Officer and Member of Scientific Advisory Board |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 
0.01 (3.12%) 
Profile
